Aesculap Launches New Sterile Container System

Aesculap, Inc. has launched its AESCULAP Aicon™ Sterile Container System. The new container has features that help streamline processes and reduce the possibility of wet sets. Aesculap will debut the new container at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference and Expo, March 19-23, in New Orleans, LA.

“As the market leader in rigid sterilization containers, we’re excited to add this innovative product to our portfolio,” said Bob Sowinski, Vice President of Sales and Marketing. “Delays in the OR can be costly. The AESCULAP Aicon Container helps reduce overall set reprocessing times and optimize processes in the SPD and the OR so that sets are ready when needed. This is one more way that we can help customers operate with greater precision.”

The new AESCULAP Aicon Container offers 100% container and basket synchronization, up to 47 percent less dry time with the Enhanced Drying System (EDS) and up to a 200 percent increase in sterile aseptic area.1

Aesculap will also spotlight its SQ.line® Surgical Instruments with features including a 50 percent reduction in difficult to inspect areas, 21 percent less force needed and 70 percent more grip compared to competitors.1

Visitors can receive in-booth continuing education during the show conducted by Nestor Hernandez, CRCST, CHL, Director of Operation Sterile Processing at Lee Health in Fort Myers, FL. This session, “Maintaining the Sterile Barrier in the Real World,” will describe the importance of maintaining the sterile barrier, focusing on wrap and rigid sterilization containers and best practices for maintaining them.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy